Atopic dermatitis (AD) is a chronic, relapsing form of inflammatory skin disease, affecting approximately 10% of children in the United States.1 AD has been associated with sleep disturbances, along with various comorbid allergic conditions, resulting in poor quality of life. In the last decade, studies have demonstrated an epidermal skin barrier defect, caused by various genetic mutations, to be an additional predisposing factor.2 Early childhood caries (ECC), a chronic diet-mediated infectious oral disease, has been reported to be the most common chronic childhood disease in the United States.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kgrYWO
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This paper proposes an enhanced ant colony optimization with dynamic mutation and ad hoc initialization, ACODM-I, for improving the accuracy...
-
2016-09-24T01-16-18Z Source: International Journal of Research in Medical Sciences Biswajit Majumder, Viral Tandel, Sandip Ghosh, Sharmis...
-
JPM, Vol. 8, Pages 5: Acknowledgement to Reviewers of Journal of Personalized Medicine in 2017 Journal of Personalized Medicine doi: 10.339...
-
Antibodies, Vol. 7, Pages 6: In-Depth Comparison of Lysine-Based Antibody-Drug Conjugates Prepared on Solid Support Versus in Solution Anti...
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
ACS Nano DOI: 10.1021/acsnano.7b02426 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h1neaG via...
-
Related Articles Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol. 2017 Apr 01;:394632017700431 Authors...
-
Hypopharyngeal Cancer Pharmaceutical and Healthcare Pipeline Review, H1 2017 Medgadget (blog) Latest Pharmaceutical and Healthcare di...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου